Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Data on the power of high betatrophin to predict cardiovascular deaths in coronary patients.

Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H.

Data Brief. 2019 Dec 12;28:104989. doi: 10.1016/j.dib.2019.104989. eCollection 2020 Feb.

2.

High betatrophin in coronary patients protects from cardiovascular events.

Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H.

Atherosclerosis. 2020 Jan;293:62-68. doi: 10.1016/j.atherosclerosis.2019.11.011. Epub 2019 Nov 15.

PMID:
31862484
3.

Evaluation of the associations between circulating microRNAs and kidney function in coronary angiography patients.

Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H.

Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F315-F321. doi: 10.1152/ajprenal.00429.2019. Epub 2019 Dec 9.

PMID:
31813253
4.

Real-time PCR based HLA-B*27 screening directly in whole blood.

Geiger K, Zach C, Leiherer A, Fraunberger P, Drexel H, Muendlein A.

HLA. 2020 Mar;95(3):189-195. doi: 10.1111/tan.13767. Epub 2019 Dec 1.

PMID:
31749313
5.

Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146.

Leiherer A, Muendlein A, Saely CH, Fraunberger P, Drexel H.

Sci Rep. 2019 Sep 6;9(1):12863. doi: 10.1038/s41598-019-49347-y.

6.

Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography.

Muendlein A, Leiherer A, Saely C, Ebner J, Geiger K, Brandtner EM, Vonbank A, Fraunberger P, Drexel H.

Data Brief. 2019 Jun 7;25:104109. doi: 10.1016/j.dib.2019.104109. eCollection 2019 Aug.

7.

Unrecognized High Occurrence of Genetically Confirmed Hereditary Carnitine Palmitoyltransferase II Deficiency in an Austrian Family Points to the Ongoing Underdiagnosis of the Disease.

Zach C, Unterkofler K, Fraunberger P, Drexel H, Muendlein A.

Front Genet. 2019 May 22;10:497. doi: 10.3389/fgene.2019.00497. eCollection 2019.

8.

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.

Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C.

Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21.

PMID:
31115844
9.

The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events.

Muendlein A, Leiherer A, Saely C, Ebner J, Geiger K, Brandtner EM, Vonbank A, Fraunberger P, Drexel H.

Atherosclerosis. 2019 Jul;286:1-6. doi: 10.1016/j.atherosclerosis.2019.04.222. Epub 2019 Apr 20.

PMID:
31051410
10.

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.

Drexel H, Leiherer A, Saely CH, Brandtner EM, Geiger K, Vonbank A, Fraunberger P, Muendlein A.

Biosci Rep. 2019 Aug 7;39(8). pii: BSR20190299. doi: 10.1042/BSR20190299. Print 2019 Aug 30.

11.

Real-time PCR based detection of the lactase non-persistence associated genetic variant LCT-13910C>T directly from whole blood.

Muendlein A, Leiherer A, Zach C, Brandtner EM, Fraunberger P, Drexel H, Geiger K.

Mol Biol Rep. 2019 Apr;46(2):2379-2385. doi: 10.1007/s11033-019-04696-9. Epub 2019 Feb 21.

PMID:
30790118
12.

Direct blood PCR: TaqMan-probe based detection of the venous thromboembolism associated mutations factor V Leiden and prothrombin c.20210G>A without DNA extraction.

Geiger K, Leiherer A, Brandtner EM, Fraunberger P, Drexel H, Muendlein A.

Clin Chim Acta. 2019 Jan;488:221-225. doi: 10.1016/j.cca.2018.11.016. Epub 2018 Nov 12.

13.

Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus.

Jaeger A, Zollinger L, Saely CH, Muendlein A, Evangelakos I, Nasias D, Charizopoulou N, Schofield JD, Othman A, Soran H, Kardassis D, Drexel H, Eckardstein AV.

Sci Rep. 2018 Sep 24;8(1):14274. doi: 10.1038/s41598-018-32274-9.

14.

Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.

Kinz E, Muendlein A.

Methods Mol Biol. 2018;1768:257-273. doi: 10.1007/978-1-4939-7778-9_15.

PMID:
29717448
15.

Data on the power of the creatinine to uromodulin ratio in serum to predict cardiovascular events in coronary patients.

Leiherer A, Muendlein A, Saely CH, Ebner J, Brandtner EM, Fraunberger P, Drexel H.

Data Brief. 2017 Mar 9;11:576-580. doi: 10.1016/j.dib.2017.03.003. eCollection 2017 Apr.

16.

The value of uromodulin as a new serum marker to predict decline in renal function.

Leiherer A, Muendlein A, Saely CH, Brandtner EM, Geiger K, Fraunberger P, Drexel H.

J Hypertens. 2018 Jan;36(1):110-118. doi: 10.1097/HJH.0000000000001527.

PMID:
28858977
17.

Serum uromodulin is associated with impaired glucose metabolism.

Leiherer A, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H.

Medicine (Baltimore). 2017 Feb;96(5):e5798. doi: 10.1097/MD.0000000000005798.

18.

Serum uromodulin is a predictive biomarker for cardiovascular events and overall mortality in coronary patients.

Leiherer A, Muendlein A, Saely CH, Ebner J, Brandtner EM, Fraunberger P, Drexel H.

Int J Cardiol. 2017 Mar 15;231:6-12. doi: 10.1016/j.ijcard.2016.12.183. Epub 2016 Dec 29.

PMID:
28089453
19.

Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease.

Muendlein A, Ebner J, Zitt E.

Nephron. 2017;135(3):242. doi: 10.1159/000453080. Epub 2016 Nov 26. No abstract available.

PMID:
27889755
20.

Prevalence of calreticulin exon 9 indel mutations in vascular risk patients.

Jaeger T, Muendlein A, Hodaie J, Untergasser G, Steurer M, Saely CH, Drexel H, Lang AH.

Thromb Res. 2016 Aug;144:215-7. doi: 10.1016/j.thromres.2016.06.034. Epub 2016 Jul 1.

PMID:
27423004

Supplemental Content

Loading ...
Support Center